Ketchikan General Hospital

Name :

Ketchikan General Hospital

Address  :

3100 Tongass Avenue

Town  :

Ketchikan

State  :

Alaska

Country  :

USA

Post Code:

99901

Phone  :

907 225 5171

Web URL  :


Description

Ketchikan General Hospital
Ketchikan General Hospital is a critical access and longterm care facility providing a variety of services including comprehensive trauma inpatient 25 beds outpatient and home health services and a longterm care facility 29 beds

Located on an island 680 air miles from Seattle Washington Ketchikan General Hospital is more selfreliant than most small rural hospitals found in the quotlower 48quot Among the services available at Ketchikan General are Diagnostic Imaging including CT MRI Nuclear Medicine and digital mammography an Intensive Care Unit home health physical and occupational therapy an accredited cancer care program uptodate technology and medical equipment an emergency physician and staff on site 24 hours a day a phase II cardiac rehabilitation program and diabetes education

The medical community is complemented by several EMT services and mediflight service from the outer islands to Ketchikan Ketchikan contracts with medivac companies to provide emergency airlifts to Seattle area hospitals for major traumas


History

Ketchikan General Hospital opened its doors in 1963 and a longterm care wing opened in 1968 The Sisters of St Joseph of Peace through their hospital services arm now known as PeaceHealth continue to operate the hospital with the same lease agreement approved by the city council in 1960
Evergreen Hospital Earns FiveYear BabyFriendly Hospital Designation

KIRKLAND Wash March 29 2012 PRNewswire via COMTEX Evergreen Healthcare today announced it has renewed its fiveyear designation as a BabyFriendly Hospital demonstrating the organizations commitment to adopting new policies and procedures that lead to improved health outcomes for newborns and families The designation is awarded by BabyFriendly US... Read More

Group B Neisseria meningitidis Vaccine Shows Promise

An investigational vaccine may represent a strong lead in the fight against group B Neisseria meningitidis according to results of a phase 2 study published online in the Lancet Administered in 3 doses over the course of 6 months a new bivalent vaccine was well tolerated and induced a strong immune response against multiple strains of the poten... Read More